Enteris BioPharma Publishes White Paper Examining Factors to Consider While Evaluating Oral Administration of Peptides

Rhea-AI Summary

Enteris BioPharma, a subsidiary of SWK Holdings (Nasdaq: SWKH), has published a white paper in Drug Development & Delivery focusing on the oral delivery of peptides. The paper discusses the challenges and opportunities in developing oral peptide therapies for chronic conditions like diabetes and obesity. Key physicochemical properties affecting oral delivery, such as molecule size and solubility, are highlighted. Enteris’ Peptelligence® platform is designed to enhance the oral bioavailability of peptides, potentially allowing oral administration for drugs typically given by injection.

Positive

• Publication of a white paper provides insights into oral peptide delivery, indicating thought leadership.
• Peptelligence® platform may enable oral administration of previously injectable peptides, widening market opportunities.
• Focus on chronic conditions may attract interest from pharmaceutical companies looking to innovate.

Negative

• None.

Physicochemical properties of peptides can provide key insights to potential success of oral delivery

BOONTON, N.J., Sept. 12, 2022 /PRNewswire/ -- Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation (Nasdaq: SWKH), announced the publication of a new white paper in Drug Development & Delivery entitled, "Key Considerations in Oral Delivery of Peptides – Factors to Consider While Evaluating Oral Administration."

The paper, authored by John Vrettos, PhD, Director of Formulation Development for Enteris BioPharma, and Kalpana Ramakrishnan, PhD, Manager of Business Development for Enteris BioPharma, explores the barriers to developing oral delivery of peptides and how pharmaceutical companies can overcome them. Oral administration of peptides offers several advantages while treating chronic conditions such as diabetes and obesity as they are less invasive and more cost effective compared to injections. The white paper is available to download via Drug Development & Delivery at https://drug-dev.com/whitepapers/whitepaper-key-considerations-in-oral-delivery-of-peptides-factors-to-consider-while-evaluating-oral-administration/.

"Molecule size, potency, and solubility are some of the key physicochemical properties that determine a peptide's suitability for oral delivery," Dr. Vrettos said. "The healthcare industry is in need of enabling drug delivery technologies with the capability to overcome barriers in oral delivery of peptides. Importantly, orally delivered medications may encourage patient compliance compared with more invasive approaches to administering drugs. Approximately 75% of peptides are delivered by injective routes, including subcutaneous injections which can be painful and difficult to incorporate into a daily routine."

Dr. Vrettos continued, "Enteris' Peptelligence^® platform offers a 'triple-action' solution comprised of our enteric coating, protease inhibitor, and permeation enhancer.  When combined, these technologies have demonstrated an ability to improve the solubility and permeation of orally delivered peptides. These properties can potentially enable oral delivery of some peptide drugs for the first time, and we are excited to share our knowledge on oral delivery of peptides through this informative whitepaper."

Peptelligence is a novel formulation technology designed to enhance the oral delivery and bioavailability of selected drugs by enhancing the permeation of such compounds that are typically injected, including peptides and BCS class III and IV small molecules, and preventing their breakdown in the digestive tract.

About Enteris BioPharma

Enteris BioPharma, Inc. is a wholly-owned subsidiary of SWK Holdings Corporation (Nasdaq: SWKH) offering total integrated contract development and manufacturing (CDMO) services for innovative formulation solutions utilizing its proprietary drug delivery technologies, Peptelligence® and ProPerma®, and contract manufacturing (CMO) services using non-proprietary technologies. The company's proprietary technologies have been the subject of numerous feasibility studies and active development programs, some of which are in clinical development. Additionally, Enteris BioPharma is advancing an innovative internal product pipeline of drug products that address significant unmet clinical needs for which there is no satisfactory treatment option. For more information on Enteris BioPharma and its proprietary oral drug delivery technologies, please visit http://www.EnterisBioPharma.com.

 

View original content:https://www.prnewswire.com/news-releases/enteris-biopharma-publishes-white-paper-examining-factors-to-consider-while-evaluating-oral-administration-of-peptides-301621732.html

SOURCE Enteris BioPharma, Inc.

FAQ

What is the significance of Enteris BioPharma's white paper on oral delivery of peptides?

The white paper discusses the challenges and solutions for developing oral peptide therapies, emphasizing the need for effective delivery technologies.

How does Enteris BioPharma's Peptelligence® platform aid in drug delivery?

Peptelligence® enhances oral bioavailability of peptides by improving solubility and stability, potentially enabling oral administration.

What advantages do orally delivered peptides offer over injections?

Oral delivery is less invasive and may improve patient compliance, as it avoids the pain and complexity of injection-based therapies.

When was the white paper on oral delivery of peptides published?

The white paper was published on September 12, 2022.

What chronic conditions can benefit from Enteris BioPharma's innovations?

Conditions such as diabetes and obesity may greatly benefit from advancements in oral peptide delivery.